Medical specialists from France tagged as investigators in clinical trials studying Prostatic Neoplasms, Castration-Resistant
Total 27 results
-
Alice Bernard TessierSeen in:
- Villejuif, Institut Gustave Roussy
Trials:- NCT05848011 (Principal Investigator)
Conditions: -
Antoine ItalianoSeen in:
- Aquitaine, Bordeaux, Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
- Bordeaux Cedex, Institut Bergonie
- Bordeaux, Bergonie Institute
- Bordeaux, Institut Bergonie
- Bordeaux, Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Trials:- NCT05009927 (Principal Investigator)
- NCT03906331 (Principal Investigator)
- NCT05440786 (Principal Investigator)
- NCT05269355 (Principal Investigator)
- NCT02834884 (Principal Investigator)
- NCT03157128 (Principal Investigator)
- NCT02029001 (Principal Investigator)
- NCT04104776 (Principal Investigator)
- NCT05920408 (Principal Investigator)
- NCT05999994 (Principal Investigator)
Conditions:- C-KIT Mutation;
- Metastatic Gastrointestinal Stromal Tumor (GIST);
- Advanced Gastrointestinal Stromal Tumor (GIST);
- Breast Cancer;
- Pancreatic Cancer;
- Non Small Cell Lung Cancer;
- Colon Cancer;
- Medullary Thyroid Cancer;
- Papillary Thyroid Cancer;
- Other Solid Tumors With Evidence of Activating RET Alteration;
- Neoplasm Metastasis;
- Sarcoma, Ewing;
- Leiomyosarcoma;
- All Tumor Types;
- Non-Small Cell Lung Cancer;
- Any Solid Tumor;
- Malignant Solid Neoplasms;
- Lymphoma, T-Cell;
- Mesothelioma, Malignant;
- Advanced Solid Tumor;
- Endometrial Cancer;
- Diffuse Large B Cell Lymphoma;
- Ovarian Clear Cell Carcinoma;
- Prostatic Neoplasms, Castration-Resistant;
- Advanced Solid Tumours;
- Adolescent;
- Neoplasms;
- Child
-
Carole HelisseySeen in:
- Ile De France, Saint-Mandé, Hopital d'Instruction des Armees BEGIN
- Saint-Mandé, HIA Begin
- Saint-Mandé, Hopital d'Instruction des Armees BEGIN
Trials:- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
- NCT04868877 (Principal Investigator)
Conditions:- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm;
- Gastric Cancer;
- Esophageal Squamous Cell Carcinoma;
- Non-Small Cell Lung Cancer Metastatic
-
Cyril AbdeddaimSeen in:
- Lille, Centre OSCAR LAMBRET
- Lille, Oscar Lambret Center
Trials:- NCT03088059 (Principal Investigator)
- NCT04104776 (Principal Investigator)
-
Delphine BorchielliniSeen in:
- AM, Nice Cedex 2, Centre Antoine-Lacassagne
- Nice, Centre Antoine Lacassagne
Trials:- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
- NCT04678362 (Principal Investigator)
- NCT05096390 (Principal Investigator)
Conditions:- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm;
- Urothelial Carcinoma;
- Papillary Renal Cell Carcinoma Type 2
-
Diego Tosi, MDSeen in:
- Herault, Montpellier, Institut régional du Cancer de Montpellier - ICM Val d'Aurelle
- Montpellier, ICM - Montpellier
Trials:- NCT05551117 (Principal Investigator)
- NCT05828459 (Principal Investigator)
Conditions:- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Independent Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Anal Neoplasm;
- Solid Tumor;
- Hematological Malignancy
-
Eric VoogSeen in:
- Le Mans, Clinique Victor Hugo
- Le Mans, Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médical
- Sarthe, Le Mans, Clinique Victor Hugo
Trials:- NCT05327530 (Principal Investigator)
- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
Conditions:- Locally Advanced or Metastatic Urothelial Carcinoma;
- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm
-
Friederike SchlurmannSeen in:
- Brest, CHRU Brest
- Bretagne, Brest, Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan
- Bretagne, Brest, Institut de cancérologie et hématologie
- Quimper, Centre Hospitalier Quimper
Trials:- NCT05288166 (Principal Investigator)
- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
- NCT04764487 (Principal Investigator)
Conditions:- Urogenital Neoplasms;
- Prostatic Neoplasms;
- Neoplasm Metastasis;
- Enzyme Inhibitors;
- Antineoplastic Agents;
- Hormones;
- Physiological Effects of Drugs;
- Antineoplastic Agents, Hormonal;
- Androgens;
- Hormones, Hormone Substitutes, and Hormone Antagonists;
- Abiraterone Acetate;
- Steroid Synthesis Inhibitors;
- Cytochrome P-450;
- Prednisone;
- Prednisolone;
- Cyclin-Dependent Kinase 4;
- Cyclin-Dependent Kinase 6;
- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm;
- Renal Cell Carcinoma Metastatic
-
Guilhem RoubaudSeen in:
- Bordeaux Cedex, INSTITUT BERGONIE - Service d'Oncologie Médicale
- Bordeaux, Institut Bergonie
- Gironde, Bordeaux, Institut Bergonie
Trials:- NCT05327530 (Principal Investigator)
- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
- NCT02869282 (Principal Investigator)
Conditions:- Locally Advanced or Metastatic Urothelial Carcinoma;
- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm;
- Prostate Cancer
-
Karim Fizazi, MDSeen in:
- Val De Marne, Villejuif, Gustave Roussy
Trials:- NCT05551117 (Principal Investigator)
Conditions:- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Independent Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Anal Neoplasm
-
Lauriane EberstSeen in:
- Strasbourg, Strasbourg Europe Institut of Cancerology
Trials:- NCT04104776 (Principal Investigator)
-
Mehdi BrahmiSeen in:
- Lyon, Centre LEON BERARD
- Lyon, Leon Berard Center
- Rhone, Lyon cedex 08, Centre LEON BERARD
Trials:- NCT04104776 (Principal Investigator)
- NCT04927260 (Principal Investigator)
- NCT04936178 (Principal Investigator)
-
Mostefa BennamounSeen in:
- Paris, Institut Mutualiste Montsouris
Trials:- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
Conditions:- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm
-
Philippe BARTHELEMY, MDSeen in:
- Bas Rhin, Strasbourg, Institut de cancerologie Strasbourg Europe (ICANS)
- Strasbourg, Institut de cancerologie Strasbourg Europe
Trials:- NCT05551117 (Principal Investigator)
- NCT06379880 (Principal Investigator)
Conditions:- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Independent Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Anal Neoplasm;
- Breast Neoplasms;
- Lung Neoplasms;
- Prostatic Neoplasms;
- Colorectal Neoplasms
-
Raffaele RattaSeen in:
- Ile De France, Suresnes, Hôpital FOCH
- Suresnes, Hôpital FOCH
Trials:- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
Conditions:- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm
-
Thomas GastinneSeen in:
- Loire-Atlantique, Nantes, CHU de Nantes - Hematologie
- Loire-Atlantique, Nantes, CHU de Nantes - Service d'Hématologie Clinique Place Alexis Ricordeau
- Loire-Atlantique, Nantes, Service d'Hématologie Clinique Place Alexis Ricordeau
- Nantes Cedex 1, Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
- Nantes, CHU Nantes
- Nantes, Hospital North
- Nantes, Nantes University Hospital Center - Hotel Dieu Hospital
- Nantes, Nantes University Hospital Center - Hotel Dieu Hospital (Satellite)
- Other, Nantes cedex 1, Centre Hospitalier Universitaire Nantes-Hotel Dieu
Trials:- NCT04662255 (Principal Investigator)
- NCT04404283 (Principal Investigator)
- NCT04104776 (Principal Investigator)
- NCT04224493 (Principal Investigator)
- NCT04446962 (Principal Investigator)
Conditions:- Lymphoma, Mantle-Cell;
- Diffuse Large B-cell Lymphoma;
- Lymphoma, T-Cell;
- Mesothelioma, Malignant;
- Advanced Solid Tumor;
- Endometrial Cancer;
- Diffuse Large B Cell Lymphoma;
- Ovarian Clear Cell Carcinoma;
- Prostatic Neoplasms, Castration-Resistant;
- Follicular Lymphoma;
- Relapsed/Refractory Follicular Lymphoma;
- Refractory Follicular Lymphoma;
- Lymphoma, Large B-Cell, Diffuse;
- Central Nervous System Neoplasms, Primary
-
Vincent Ribrag, MDSeen in:
- Val De Marne, Villejuif cedex, Institut Gustave Roussy
- Villejuif, Gustave Roussy
Trials:- NCT05176691 (Principal Investigator)
- NCT04104776 (Principal Investigator)
Conditions:- Follicular Lymphoma;
- Waldenstrom Macroglobulinemia;
- Lymphoplasmacytic Lymphoma;
- NHL;
- DLBCL;
- Richter Syndrome;
- CLL/SLL;
- MCL;
- MZL;
- Lymphoma, T-Cell;
- Mesothelioma, Malignant;
- Advanced Solid Tumor;
- Endometrial Cancer;
- Diffuse Large B Cell Lymphoma;
- Ovarian Clear Cell Carcinoma;
- Prostatic Neoplasms, Castration-Resistant
-
Xavier ArtignanSeen in:
- Ille Et Vilaine, Saint-Grégoire, Centre Hospitalier Prive Saint-Gregoire
- Saint-Gregoire, Centre Hospitalier Prive Saint-Gregoire
- Saint-Grégoire, CHP Saint Gregoire
- Saint-Grégoire, CHP St Grégoire
Trials:- NCT02799706 (Principal Investigator)
- NCT05848011 (Principal Investigator)
- NCT05551117 (Principal Investigator)
- NCT04764487 (Principal Investigator)
Conditions:- Prostate Cancer;
- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule;
- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Anal Neoplasm;
- Renal Cell Carcinoma Metastatic
Clinical Trials on Prostatic Neoplasms, Castration-Resistant
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Arcus Biosciences, Inc.Gilead SciencesActive, not recruitingProstatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic NeoplasmsUnited States, Canada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingProstate Cancer | Refractory Cancer | Castration Resistant Prostatic CancerUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedMetastatic Prostate Cancer | Castration Resistant Prostatic CancerUnited States